Streetbeat News

Products Services

PFE

Pfizer Inc has agreed to provide the U.S. government with 1 million treatment courses for a strategic national stockpile. The company will receive credit for future NDA-labeled treatment courses. Pfizer expects additional clarification on global vaccination and treatment rates by the end of the year.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 8:40 pm

AAPL

EA

GOOGL

Electronic Arts (EA) is developing a new free-to-play, turn-based RPG-like soccer game called FC Tactical, set to launch in 2024 for mobile devices. The game will feature over 5,000 players from 10 leagues and will offer various modes. FC Tactical is open for pre-registration on Google Play Store and Apple's App Store.

Portfolio Pulse from Franca Quarneti

October 13, 2023 | 8:37 pm

SDIG

Stronghold Digital Mining, Inc. (NASDAQ:SDIG) announced that it mined 196 Bitcoin in September 2023, generating approximately $0.2 million in energy revenue. The company experienced an unplanned outage at its Scrubgrass power plant, affecting operations. However, it achieved an all-time-high hash rate of 3.5 exahash per second by the end of the month. Stronghold also entered into a Managed Services Agreement with Frontier Mining to optimize its data centers.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 8:35 pm

PFE

Pfizer has revised its FY23 adjusted diluted EPS guidance to $1.45-$1.65, down from the original range of $3.25-$3.45. The company also anticipates full-year 2023 revenues to be $58.0 to $61.0 billion, a decrease from the previous guidance of $67.0 to $70.0 billion. This is due to lower-than-expected revenues from its COVID products, Paxlovid and Comirnaty. Pfizer also recorded a non-cash charge of $5.5 billion due to inventory write-offs for these products. However, the company expects to deliver approximately $1.0 billion in savings in 2023 through its cost realignment program.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 8:34 pm

PFE

Pfizer has revised its 2023 revenue guidance to $58B-$61B, down from $66.02B, due to changes in its Covid products. The company has amended its supply agreement with the U.S. government for Paxlovid, reducing its revenue guidance for the drug by $7B. Pfizer will commercialize Paxlovid in the U.S. starting January 1, 2024. The company also plans to launch a cost realignment program expected to deliver savings of at least $3.5B.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 8:32 pm

MSFT

Microsoft Corporation is offering a new Xbox Series S bundle for the holiday shopping season. The bundle includes an Xbox Series S console and a three-month Xbox Game Pass Ultimate membership for $299, the same price as a standalone Xbox Series S. The Game Pass is valued at $50 for these three months. The bundle also includes access to the Game Pass library, EA Play games, Game Pass for Windows games, and the ability to stream some Xbox titles to other devices.

Portfolio Pulse from Franca Quarneti

October 13, 2023 | 8:18 pm

ICPT

The European Medicines Agency (EMA) has begun a review of Ocaliva, a medicine used to treat primary biliary cholangitis (PBC), following the results of two studies. The studies failed to show that Ocaliva was more effective than a placebo, and side effects, including serious ones, occurred more frequently in patients treated with Ocaliva. The EMA will assess the impact of these findings on the overall benefit-risk balance of Ocaliva and make a recommendation on whether the medicine's marketing authorisation in the EU should be amended.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 7:57 pm

F

Ford Motor Company (F) has announced a temporary reduction in shifts at its Michigan electric vehicle plant due to multiple constraints. The company will cut one of three shifts at the plant, potentially affecting production rates.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 7:51 pm

RVMD

Revolution Medicines has announced preliminary clinical data for RMC-6236 and RMC-6291, leading to a rise in the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 7:45 pm

RVMD

Revolution Medicines, Inc. (NASDAQ:RVMD) has presented encouraging preliminary clinical data for RMC-6236 and RMC-6291, its RAS(ON) Inhibitors, at the 2023 AACR-NCI-EORTC International Conference. The data shows oral bioavailability, a well-tolerated safety profile, and preliminary evidence of anti-tumor activity across multiple RAS mutations. The company plans to continue evaluating these compounds with the goal of bringing new and effective therapies to patients living with RAS-addicted cancers.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 7:44 pm